Fate Therapeutics FT819 shows 100% renal response in lupus nephritis
Fate Therapeutics has presented updated Phase 1 data for FT819, its iPSC-derived, off-the-shelf anti-CD19 CAR T-cell candidate, in patients with systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN). The data, presented in an oral session at the American Society of Nephrology Kidney Week 2026 in Denver, showed that every patient evaluable at Month 6 who received FT819 alongside the bendamustine conditioning regimen selected for the ongoing Phase 2 RECLAIM-LN study achieved either a complete renal response or a primary efficacy renal response. Mean urine protein-to-creatinine ratio, a standard measure of kidney damage in LN, fell by approximately 50% from baseline in that cohort.
The safety readout across all 29 autoimmune patients treated with a single dose of FT819 under less-intensive, fludarabine-free conditioning was notable for the absence of several toxicities associated with conventional autologous CAR T therapy. No dose-limiting toxicities, no ICANS, no graft-versus-host disease, no IEC-HS and no deaths were reported. Low-grade CRS occurred in five patients; Grade 3 or higher infections were recorded in two patients, both urinary tract infections. The company said FT819 is already being administered in outpatient settings in the United States.
Jonathan Graf, Professor of Clinical Medicine at the University of California San Francisco and the presenting investigator, said patients receiving even the lowest doses of FT819 were achieving significant clinical responses "while showing no signs of serious toxicity," adding that he looked forward to full results from the completed Phase 1 study.
Translational signals and the RECLAIM-LN Phase 2 study
Beyond renal endpoints, the dataset included translational evidence supporting the mechanism. FT819 drove deep B-cell depletion in peripheral blood and in secondary lymphoid tissue, followed by reconstitution dominated by less-differentiated, naïve B cells. The 50 most abundant B-cell receptor clones present at baseline were absent by Month 1 and did not re-emerge by Month 6, a finding the company characterises as consistent with an immune reset. Physician Global Assessment scores fell by approximately 75% from baseline by Month 6, and patient-reported fatigue, measured using the FACIT-Fatigue scale, improved twofold, moving out of the range associated with moderate-to-severe fatigue.
These data are intended to support the ongoing RECLAIM-LN study (NCT07570862), a Phase 2 potentially registrational trial in refractory, moderate-to-severe SLE with LN using the same bendamustine conditioning regimen.
Market and competitive context
The CAR T-cell autoimmune field has moved quickly since early autologous CAR T data in lupus generated significant clinical interest. Autologous programmes from academic centres in Germany and commercial developers have reported deep and durable responses in small SLE cohorts, but manufacturing complexity and the requirement for patient-specific cell collection limit scalability. Fate's FT819, derived from a clonal iPSC master cell bank, is positioned as an off-the-shelf alternative that can be stocked in inventory and administered without the lead time associated with patient-derived manufacture.
The avoidance of fludarabine in conditioning is also clinically relevant for LN patients, since fludarabine is renally cleared and requires dose adjustment in those with impaired renal function, the very population this therapy targets. If the tolerability and renal response data hold in the larger Phase 2 cohort, the outpatient, on-demand model could represent a meaningful practical advantage over both autologous CAR T approaches and existing standard-of-care options for refractory LN, which remain limited. Investors will watch RECLAIM-LN enrolment pace and the timing of interim data as the key near-term indicators of programme progress.